Back to Top
Ichorbio Citations
| Year | Article Title | ichorbio Product Cited |
|---|---|---|
| 2025 | Gambles, MT et al. Two-component T-cell immunotherapy enables antigen pre-targeting to reduce cytokine release without forfeiting efficacy, Nanomedicine: Nanotechnology, Biology and Medicine, Volume 67, 2025, 102825. | ICH1002 |
| 2025 | Li, S. et al. Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma. Adv. Healthcare Mater. (2025): e02156. | ICH1002 |
| 2025 | Gambles, MT et al. Two-component T-cell immunotherapy enables antigen pre-targeting to reduce cytokine release without forfeiting efficacy, Nanomedicine: Nanotechnology, Biology and Medicine, Volume 67, 2025, 102825. | ICH1011 |
| 2025 | Saggau, Carina et al. Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases. Immunity, Volume 57, Issue 10, 2416 - 2432.e8 | ICH1024 |
| 2025 | WNT4 promotes macrophage polarization via granulosa cell M-CSF and reduces granulosa cell apoptosis in endometriosis | ICH1026 |
| 2025 | Cao et al. Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation. Journal of Nanobiotechnology | ICH1042 |
| 2025 | Cao et al. Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation. Journal of Nanobiotechnology | ICH1043 |
| 2025 | Tang, Dongyang et al. Augment proteasome inhibitor efficacy activates CD8+ T cell-mediated antitumor immunity in breast cancer. Cell Reports Medicine, Volume 6, Issue 7, 102211 | ICH1045 |
| 2025 | Pircher et al. MHC I tetramer staining tends to overestimate the number of functionally relevant self-reactive CD8 T cells in the preimmune repertoire. European Journal of Immunology. | ICH1073 |
| 2025 | M. Stepanechko et al. Single Treatment Boiling Histotripsy Focused Ultrasound Ablation Neither Negates nor Enhances the Activity of α-CD40 in a Pancreatic Cancer Model. IEEE Transactions on Biomedical Engineering | ICH1073 |
| 2025 | Cao et al. Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation. Journal of Nanobiotechnology | ICH1077 |
| 2025 | Rodriguez-Baena, Francisco Javier et al. Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases. Cancer Cell, Volume 43, Issue 3, 413 - 427.e9 | ICH1084 |
| 2025 | Chen et al. NAT10/ac4C/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical Cancer. Advanced Science | ICH1086 |
| 2025 | Lin et al. Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice. Cell Reports | ICH1086 |
| 2025 | Liang B. et al. SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression. Cancer Research Communications (2023) 3 (11): 2412–2419. | ICH1091 |
| 2025 | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | ICH1094 |
| 2025 | Ye, Junjie et al. Oncolytic vaccinia virus expressing non-secreted decoy-resistant IL-18 mutein elicits potent antitumor effects with enhanced safety. Molecular Therapy Oncology, Volume 33, Issue 3, 201022 | ICH1096 |
| 2025 | Braun, Lukas M. et al. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell, Volume 43, Issue 2, 269 - 291.e19 | ICH1096 |
| 2025 | A TrkB agonist prodrug prevents bone loss via inhibiting asparagine endopeptidase and increasing osteoprotegerin | ICH1114 |
| 2025 | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | ICH1132 |
| 2025 | Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment | ICH1132 |
| 2025 | PD-1 Blockade Restores the Proliferation of Peripheral Blood Lymphocyte and Inhibits Lymphocyte Apoptosis in a BALB/c Mouse Model of CP BVDV Acute Infection | ICH1132 |
| 2025 | Kauffman et al. PSGL-1 Blockade Induces Classical Activation of Human Tumor-Associated Macrophages. Cancer Research Communications 2023 | ICH1132 |
| 2025 | Liang et al. SIX4 Controls STING Expression Enhancing anti-PD-1 Efficacy. bioRxiv | ICH1132 |
| 2025 | Xu et al. One-carbon unit supplementation fuels tumor-infiltrating T cells and augments checkpoint blockade. bioRxiv | ICH1132 |
| 2025 | Shyr, C.-R. et al. Evaluating Therapeutic Efficacy of Intravesical Xenogeneic Urothelial Cell Treatment Alone and in Combination with Chemotherapy or Immune Checkpoint Inhibition in a Mouse Non-Muscle-Invasive Bladder Cancer Model. Cancers 2025, 17, 2448. | ICH1132 |
| 2025 | Roichman et al. Dietary Fiber Lacks a Consistent Effect on Immune Checkpoint Blockade Efficacy Across Diverse Murine Tumor Models. Cancer Res 2025 | ICH1132 |
| 2025 | Braun, Lukas M. et al. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell, Volume 43, Issue 2, 269 - 291.e19 | ICH1132 |
| 2025 | Braun LM, Zeiser, R. Protocol to study in vivo organ-specific migration of apoptotic splenocytes in mice with tumor and immune checkpoint inhibitor-induced colitis, STAR Protocols, Volume 6, Issue 2, 2025, 103878. | ICH1132 |
| 2025 | Levin, Sapir et al. Immature monocytic cells within tumors differentiate into immunosuppressive cells in resistant tumors to immunotherapy. iScience, Volume 28, Issue 8, 113141 | ICH1132 |
| 2025 | Patel, A. et al. Targeting Neuronal Nitric Oxide Synthase (nNOS) as a Novel Approach to Enhancing the Anti-Melanoma Activity of Immune Checkpoint Inhibitors. Pharmaceutics 2025, 17, 691. | ICH1132 |
| 2025 | Dai, Y., Aizenbud, L., Qin, K. et al. Humoral determinants of checkpoint immunotherapy. Nature 644, 527–536 (2025). | ICH1135 |
| 2025 | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | ICH1137 |
| 2025 | Tang, Dongyang et al. Augment proteasome inhibitor efficacy activates CD8+ T cell-mediated antitumor immunity in breast cancer. Cell Reports Medicine, Volume 6, Issue 7, 102211 | ICH2243 |
| 2025 | Chuah, S. et al. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. Journal of Hepatology. Volume 77, Issue 3, 2022, Pages 683-694, | ICH2244 |
| 2025 | Roichman et al. Dietary Fiber Lacks a Consistent Effect on Immune Checkpoint Blockade Efficacy Across Diverse Murine Tumor Models. Cancer Res 2025 | ICH2244 |
| 2025 | Braun, Lukas M. et al. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity Cancer Cell, Volume 43, Issue 2, 269 - 291.e19 | ICH2244 |
| 2025 | Patel, A. et al. Targeting Neuronal Nitric Oxide Synthase (nNOS) as a Novel Approach to Enhancing the Anti-Melanoma Activity of Immune Checkpoint Inhibitors. Pharmaceutics 2025, 17, 691. | ICH2244 |
| 2025 | Liang B. et al. SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression. Cancer Research Communications (2023) 3 (11): 2412–2419. | ICH2244 |
| 2025 | PD-1 Blockade Restores the Proliferation of Peripheral Blood Lymphocyte and Inhibits Lymphocyte Apoptosis in a BALB/c Mouse Model of CP BVDV Acute Infection | ICH2244 |
| 2025 | IκBζ controls IL-17-triggered gene expression program in intestinal epithelial cells that restricts colonization of SFB and prevents Th17-associated pathologies | ICH2246 |
| 2025 | Travelli et al. Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer. Journal for ImmunoTherapy of Cancer | ICH2248 |
| 2025 | Braun, Lukas M. et al. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell, Volume 43, Issue 2, 269 - 291.e19 | ICH2250 |
| 2025 | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | ICH2251 |
| 2025 | Gravina, A., Tediashvili, G., Rajalingam, R. et al. Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression. Nat Biotechnol 41, 717–727 (2023). | ICH4002 |
| 2025 | Gravina et al. Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity. Cell Stem Cell 30, 1538–1548 | ICH4002 |
| 2025 | Iadonato et al. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors. Front Immunol. 2023; 14: 1311658. | ICH4002 |
| 2025 | SARS-CoV-2 triggers complement activation through interactions with heparan sulfate | ICH4005 |
| 2025 | Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates | ICH4007 |
| 2025 | Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates | ICH4008 |
| 2025 | Narsimhan et al. Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies. Analytical Chemistry | ICH4009 |
| 2025 | Narsimhan et al. Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies. Analytical Chemistry | ICH4011 |
| 2025 | Ketchemen, JP et al. Preclinical characterization of 3p-C-DEPA-NCS and 3p-C-DEPA-TFP-PEG4 as potential Actinium-225 bifunctional chelators using DOTA-NCS and macropa-NCS as benchmarks., 17 June 2025, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-6813431/v1] | ICH4013 |
| 2025 | Ketchemen, JP et al. Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody–Drug Radioconjugate. Clin Cancer Res (2025) 31 (4): 685–696. | ICH4013 |
| 2025 | RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model | ICH4019 |
| 2025 | Narsimhan et al. Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies. Analytical Chemistry | ICH4019 |
| 2025 | Barakat, R., Al-Sarraf, H. & Redzic, Z. Hypoxemia exerts detrimental effects on the choroid plexuses and cerebrospinal fluid system in rats. Fluids Barriers CNS 22, 27 (2025). [https://doi.org/10.1186/s12987-024-00613-w] | ICH4022 |
| 2025 | Dipasquale et al. Biosimilars in Pediatric IBD: Updated Considerations for Disease Management | ICH4035 |
| 2025 | Parrish II, RH. Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary. Gastroenterology Insights | ICH4035 |
| 2025 | Giang, K.A. et al. An Anti-BCMA Affibody Affinity Protein for Therapeutic and Diagnostic Use in Multiple Myeloma. Int. J. Mol. Sci. 2025, 26, 5186. [https://doi.org/10.3390/ijms26115186] | ICH5011 |
| 2025 | Lee et al. A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity. Journal of Experimental & Clinical Cancer Research | ICH5015 |
| 2025 | Huang et al. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity. Journal of Translational Medicine | ICH5023 |
| 2025 | Mancusi et al. Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation. Int. J. Mol. Sci. 2023, 24(22), 16105 | ICH5025 |
| 2025 | Fausther-Bovendo, H. et al. Rapid In Vivo Screening of Monoclonal Antibody Cocktails Using Hydrodynamic Delivery of DNA-Encoded Modified Antibodies. Biomedicines 2025, 13, 637. | ICH5071 |
| 2025 | Arbués A. et al. (2025) Soluble immune mediators orchestrate protective in vitro granulomatous responses across Mycobacterium tuberculosis complex lineages eLife 13:RP99062. | ICH5133 |
| 2025 | Kummer, N. et al. Anti-amyloid antibody effects on Aβ-42 protein aggregates profiled using nanospectroscopy. bioRxiv 2025.07.17.665305; | ICH5219 |
| 2024 | Majewska, J., Agrawal, A., Mayo, A. et al. p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells. Nat Cell Biol 26, 1336–1345 (2024). | ICH1086 |
| 2024 | Majewska, J., Agrawal, A., Mayo, A. et al. p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells. Nat Cell Biol 26, 1336–1345 (2024). | ICH1091 |
| 2024 | Ye, J.; Intratumoral Delivery of Interleukin 9 via Oncolytic Vaccinia Virus Elicits Potent Antitumor Effects in Tumor Models. Cancers 2024, 16, 1021. | ICH1096 |
| 2024 | Mine et al. TYK2 signaling promotes the development of autoreactive CD8+ cytotoxic T lymphocytes and type 1 diabetes. Nature Communications volume 15, Article number: 1337 (2024) | ICH1110 |
| 2024 | Benguigui et al. Interferon-stimulated neutrophils as a predictor of immunotherapy response. 2024, Cancer Cell 42, 253–265 | ICH1132 |
| 2024 | Mine et al. TYK2 signaling promotes the development of autoreactive CD8+ cytotoxic T lymphocytes and type 1 diabetes. Nature Communications volume 15, Article number: 1337 (2024) | ICH1135 |
| 2024 | Ilija Brizić, Andrea Mihalić, Daria Kveštak et al. Persistently primed microglia restrict the reactivation of latent cytomegalovirus at the expense of neuronal synaptic connectivity, 03 October 2024, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-5144336/v1] | ICH1141 |
| 2024 | Majewska, J., Agrawal, A., Mayo, A. et al. p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells. Nat Cell Biol 26, 1336–1345 (2024). | ICH2243 |
| 2024 | Gaifem J, et al. 2024. Akkermansia muciniphila and Parabacteroides distasonis synergistically protect from colitis by promoting ILC3 in the gut. mBio 15:e00078-24. | ICH2243 |
| 2024 | Benguigui et al. Interferon-stimulated neutrophils as a predictor of immunotherapy response. 2024, Cancer Cell 42, 253–265 | ICH2244 |
| 2024 | Liang B. et al. Antagonistic roles of cGAS/STING signaling in colorectal cancer chemotherapy. Front Oncol. 2024 Oct 14;14:1441935. | ICH2244 |
| 2024 | Ketchemen JP et al. Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer. Eur J Nucl Med Mol Imaging (2024). | ICH4013 |
| 2024 | Giannos, S.A., Kraft, E.R., Luisi, J.D. et al. Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits. Pharm Res 41, 1247–1256 (2024). | ICH4031 |
| 2024 | McElroy, W. & Heger, CD. Development of the SupersonicIEF Method for High-Throughput Charge Variant Analysis. Electrophoresis. 45, 21-22, 2024, 1968-1975. | ICH5080 |
| 2024 | T cell help induces Myc transcriptional bursts in germinal center B cells during positive selection | ICH1042 |
| 2024 | Intratumoral Delivery of Interleukin 9 via Oncolytic Vaccinia Virus Elicits Potent Antitumor Effects in Tumor Models | ICH1096 |
| 2024 | TYK2 signaling promotes the development of autoreactive CD8+ cytotoxic T lymphocytes and type 1 diabetes | ICH1110 |
| 2024 | Interferon-stimulated neutrophils as a predictor of immunotherapy response | ICH1132 |
| 2024 | TYK2 signaling promotes the development of autoreactive CD8+ cytotoxic T lymphocytes and type 1 diabetes | ICH1135 |
| 2024 | Akkermansia muciniphila and Parabacteroides distasonis synergistically protect from colitis by promoting ILC3 in the gut | ICH2243 |
| 2024 | Interferon-stimulated neutrophils as a predictor of immunotherapy response | ICH2244 |
| 2024 | Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer | ICH4013 |
| 2023 | Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity. | ICH4002 |
| 2023 | Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation. | ICH5025 |
| 2023 | A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors | ICH4002 |
| 2023 | One-carbon unit supplementation fuels tumor-infiltrating T cells and augments checkpoint blockade | IHC1132 |
| 2023 | A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity | ICH5015 |
| 2023 | Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer | ICH2248 |
| 2023 | Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies | ICH4011, ICH4009, ICH4019 |
| 2023 | Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation | ICH1077, ICH1042, and ICH1043 |
| 2023 | Aconite aqueous extract inhibits the growth of hepatocellular carcinoma through CCL2-dependent enhancement of natural killer cell infiltration | ICH1128UL |
| 2023 | WNT4 promotes macrophage polarization via granulosa cell M-CSF and reduces granulosa cell apoptosis in endometriosis | ICH1026 |
| 2023 | MHC I tetramer staining tends to overestimate the number of functionally relevant self-reactive CD8 T cells in the preimmune repertoire | ICH1073 |
| 2023 | NAT10/ac4C/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical Cancer | ICH1086 |
| 2023 | p16-dependent upregulation of PD-L1 impairs immunosurveillance of senescent cells | ICH1086, ICH2243 |
| 2023 | Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice | ICH1086 |
| 2023 | Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment | ICH1132 |
| 2023 | PSGL-1 Blockade Induces Classical Activation of Human Tumor-Associated Macrophages. | ICH1132 |
| 2023 | SIX4 Controls STING Expression Enhancing anti-PD-1 Efficacy | ICH1132 |
| 2023 | A magneto-activated nanoscale cytometry platform for molecular profiling of small extracellular vesicles | ICH1132UL |
| 2023 | Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression | ICH4002 |
| 2023 | Topical Delivery of Ranibizumab drops in Anti-aggregation diluent formula for retinal Delivery in Rabbits | ICH4031 |
| 2023 | A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity | ICH5023 |
| 2023 | Vascular Endothelial Growth Factor Receptor 1 Targeting Fusion Polypeptides with Stimuli-Responsiveness for Anti-angiogenesis | |
| 2023 | Activatable near-infrared probes for the detection of specific populations of tumour-infiltrating leukocytes in vivo and in urine | |
| 2022 | A TrkB agonist prodrug prevents bone loss via inhibiting asparagine endopeptidase and increasing osteoprotegerin | ICH1114 |
| 2022 | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | ICH1132, ICH1094, ICH1137, ICH2251, ICH2244 |
| 2022 | IκBζ controls IL-17-triggered gene expression program in intestinal epithelial cells that restricts colonization of SFB and prevents Th17-associated pathologies | ICH2246 |
| 2022 | SARS-CoV-2 Triggers Complement Activation through Interactions with Heparan Sulfate | ICH4005 |
| 2022 | RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model | ICH4019 |
| 2022 | Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates | ICH4008, ICH4007 |
| 2022 | Biosimilars in Pediatric IBD: Updated Considerations for Disease Management | ICH4035 |
| 2021 | PD-1 Blockade Restores the Proliferation of Peripheral Blood Lymphocyte and Inhibits Lymphocyte Apoptosis in a BALB/c Mouse Model of CP BVDV Acute Infection | ICH1132, ICH2244 |
| 2021 | Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary | ICH4035 |
Please see below for a full list of ichorbio publications arranged in date order. ichorbio currently has 32 citations in total.
ichorbio Publications for Product Code ICH1026
Citations for Bulk anti-human HLA-DR antibody (L243)
| Yuan et al. | WNT4 promotes macrophage polarization via granulosa cell M-CSF and reduces granulosa cell apoptosis in endometriosis | Cytokine | 2023 |
ichorbio Publications for Product Code ICH1042
Citations for anti-CD4 In Vivo Antibody - Low Endotoxin (GK1.5)
| Cao et al. | Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation | Journal of Nanobiotechnology | 2023 |
ichorbio Publications for Product Code ICH1043
Citations for ichorbio's anti-CD8 In Vivo Antibody - Low Endotoxin (YTS-169)
| Cao et al. | Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation | Journal of Nanobiotechnology | 2023 |
ichorbio Publications for Product Code ICH1073
Citations for ichorbio's anti-CD40 In Vivo Antibody - Low Endotoxin (FGK4.5)
| Pircher et al. | MHC I tetramer staining tends to overestimate the number of functionally relevant self-reactive CD8 T cells in the preimmune repertoire | European Journal of Immunology | 2023 | ICH1073 |
ichorbio Publications for Product Code ICH1077
Citations for ichorbio's Anti-Mouse CD209b In Vivo Antibody – Low Endotoxin (22D1)
| Cao et al. | Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation | Journal of Nanobiotechnology | 2023 | ICH1077 |
ichorbio Publications for Product Code ICH1086
Citations for ichorbio's anti-PD-L1 In Vivo Antibody - Low Endotoxin (10F.9G2)
| Chen et al. | NAT10/ac4C/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical Cancer | Advanced Science | 2023 | ICH1086 |
| Majewska et al. | p16-dependent upregulation of PD-L1 impairs immunosurveillance of senescent cells | bioRxiv | 2023 | ICH1086 |
| Lin et al. | Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice | Cell Reports | 2023 | ICH1086 |
ichorbio Publications for Product Code ICH1094
Citations for ichorbio's anti-CD120a In Vivo Antibody - Low Endotoxin (55R-170)
| Chuah et al. | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | Journal of Hepatology | 2022 | ICH1094 |
ichorbio Publications for Product Code ICH1114
Citations for ichorbio's anti-RANKL In Vivo Antibody - Low Endotoxin (IK22/5)
| Xiong et al. | A TrkB agonist prodrug prevents bone loss via inhibiting asparagine endopeptidase and increasing osteoprotegerin | Nature Communications | 2022 | ICH1114 |
ichorbio Publications for Product Code ICH1128UL
Citations for ichorbio's anti-NK1.1 In Vivo Antibody - Low Endotoxin (PK136)
| Yang et al. | Aconite aqueous extract inhibits the growth of hepatocellular carcinoma through CCL2-dependent enhancement of natural killer cell infiltration | Journal of Integrative Medicine | 2023 | ICH1128UL |
ichorbio Publications for Product Code ICH1132
Citations for ichorbio's anti-PD-1 (RMP1-14)
| Wu et al. | Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment | Journal of Advanced Research | 2023 | ICH1132 |
| Kauffman et al. | PSGL-1 Blockade Induces Classical Activation of Human Tumor-Associated Macrophages. | Cancer Research Communications 2023 | 2023 | ICH1132 |
| Liang et al. | SIX4 Controls STING Expression Enhancing anti-PD-1 Efficacy | bioRxiv | 2023 | ICH1132 |
| Chuah et al. | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | Journal of Hepatology | 2022 | ICH1132 |
| Liu et al. | PD-1 Blockade Restores the Proliferation of Peripheral Blood Lymphocyte and Inhibits Lymphocyte Apoptosis in a BALB/c Mouse Model of CP BVDV Acute Infection | Frontiers in Immunology | 2021 | ICH1132 |
| Chen et al. | One-carbon unit supplementation fuels tumor-infiltrating T cells and augments checkpoint blockade | bioRxiv | 2023 | ICH1132 |
| Chuah et al. | A magneto-activated nanoscale cytometry platform for molecular profiling of small extracellular vesicles | Nature Communications | 2023 | ICH1132UL |
ichorbio Publications for Product Code ICH1137
Citations for ichorbio's anti-TNFR2 In Vivo Antibody - Low Endotoxin (TR75-54.7)
| Chuah et al. | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | Journal of Hepatology | 2022 | ICH1137 |
ichorbio Publications for Product Code ICH2244
Citations for ichorbio's anti-Rat IgG2a isotype control
| Chuah et al. | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | Journal of Hepatology | 2022 | ICH2244 |
| Liu et al. | PD-1 Blockade Restores the Proliferation of Peripheral Blood Lymphocyte and Inhibits Lymphocyte Apoptosis in a BALB/c Mouse Model of CP BVDV Acute Infection | Frontiers in Immunology | 2021 | ICH2244 |
ichorbio Publications for Product Code ICH2246
Citations for ichorbio's Rat IgG1 Isotype Control for In Vivo - Low Endotoxin (GL113)
| Yamazaki et al. | IκBζ controls IL-17-triggered gene expression program in intestinal epithelial cells that restricts colonization of SFB and prevents Th17-associated pathologies | mucosal immunology | 2022 | ICH2246 |
ichorbio Publications for Product Code ICH2248
Citations for ichorbio's Mouse IgG1 Isotype Control for In Vivo - Low Endotoxin (HKSP84)
| Travelli et al. | Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer | Journal for ImmunoTheraphy of Cancer | 2023 | ICH2248 |
| Majewska et al. | p16-dependent upregulation of PD-L1 impairs immunosurveillance of senescent cells | bioRxiv | 2023 | ICH2248 |
ichorbio Publications for Product Code ICH2251
Citations for ichorbio's Armenian Hamster IgG Isotype Control for In Vivo - Low Endotoxin (PIP)
| Chuah et al. | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | Journal of Hepatology | 2022 | ICH2251 |
ichorbio Publications for Product Code ICH4002
Citations for ichorbio's research grade alemtuzumab biosimilar
| Gravina et al. | Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression | Nature Biotechnology | 2023 | ICH4002 |
| Iadonato et al. | A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors | Front Immunol. 2023; 14: 1311658. | 2023 | ICH4002 |
| Gravina et al. | Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity. | Cell Stem Cell 30, 1538–1548 | 2023 | ICH4002 |
ichorbio Publications for Product Code ICH4005
Citations for ichorbio's Eculizumab Biosimilar - Research Grade
| Lo et al. | SARS-CoV-2 Triggers Complement Activation through Interactions with Heparan Sulfate | bioRxiv | 2022 | ICH4005 |
ichorbio Publications for Product Code ICH4007
Citations for ichorbio's Matuzumab Biosimilar - Research Grade
| Tikum et al. | Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates | Pharmaceutics | 2022 | ICH4007 |
ichorbio Publications for Product Code ICH4008
Citations for ichorbio's Nimotuzumab Biosimilar - Research Grade
| Tikum et al. | Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates | Pharmaceutics | 2022 | ICH4008 |
ichorbio Publications for Product Code ICH4009
Citations for ichorbio's Nivolumab Biosimilar - Research Grade
| Narsimhan et al. | Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies | Analytical Chemistry | 2023 | ICH4009 |
ichorbio Publications for Product Code ICH4011
Citations for ichorbio's Rituximab Biosimilar - Research Grade
| Narsimhan et al. | Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies | Analytical Chemistry | 2023 | ICH4011 |
ichorbio Publications for Product Code ICH4019
Citations for ichorbio's Denosumab Biosimilar - Research Grade
| Narsimhan et al. | Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies | Analytical Chemistry | 2023 | ICH4019 |
| Pape et al. | RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model | Journal of Tissue Engineering | 2022 | ICH4019 |
ichorbio Publications for Product Code ICH4031
Citations for ichorbio's Ranibizumab Biosimilar - Research Grade
| Gupta et al. | Topical Delivery of Ranibizumab drops in Anti-aggregation diluent formula for retinal Delivery in Rabbits | ARVO Annual Meeting Abstract | 2023 | ICH4031 |
ichorbio Publications for Product Code ICH4035
Citations for ichorbio's Vedolizumab Biosimilar - Research Grade
| Dipasquale et al. | Biosimilars in Pediatric IBD: Updated Considerations for Disease Management | Biologics | 2022 | ICH4035 |
| Parrish II, RH | Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary | Gastroenterology Insights | 2021 | ICH4035 |
ichorbio Publications for Product Code ICH5015
Citations for ichorbio's Urelumab Biosimilar - Research Grade
| Lee et al. | A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity | Journal of Experimental & Clinical Cancer Research | 2023 | ICH5015 |
ichorbio Publications for Product Code ICH5023
Citations for ichorbio's Theralizumab Biosimilar - Research Grade
| Huang et al. | A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity | Journal of Translational Medicine | 2023 | ICH5023 |
